Cardiovascular-metabolic impact of adiponectin and aquaporin

Endocrine Journal

Volumn 60, Issue 3, 2013, Pages 251-259

  Maeda, Norikazu ^a   Funahashi, Tohru ^a   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adipocytes; Adiponectin; Aquaporin; Cardiovascular diseases; Metabolic syndrome

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ADIPONECTIN; ALDOSTERONE; ANDROGEN; AQUAPORIN; AQUAPORIN 2; AQUAPORIN 7; AQUAPORIN 9; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CADHERIN; CD36 ANTIGEN; COLLAGEN TYPE 10; COLLAGEN TYPE 8; COMPLEMENT COMPONENT C1Q; FATTY ACID BINDING PROTEIN; FATTY ACID TRANSPORTER; GLYCEROL; GLYCEROL KINASE; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; NATRIURETIC PEPTIDE RECEPTOR 1; NATRIURETIC PEPTIDE RECEPTOR 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; T CADHERIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPONECTIN GENE; AQUAPORIN 7 GENE; AQUAPORIN 9 GENE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENE; GENE EXPRESSION; HEART FAILURE; HORMONE RECEPTOR INTERACTION; HUMAN; HYPOADIPONECTINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; LIPOGENESIS; METABOLIC DISORDER; MINERALOCORTICOID RECEPTOR GENE; MULTIPLE ORGAN FAILURE; NATRIURETIC PEPTIDE RECEPTOR 3 GENE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ADIPOCYTES; ADIPONECTIN; AQUAPORINS; CARDIOVASCULAR SYSTEM; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTRA-ABDOMINAL FAT; MALE; METABOLIC SYNDROME X; OBESITY;

EID: 84875881084     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ13-0016     Document Type: Review

References (96)

1. Matsuzawa Y (2006) Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 3: 35-42.
2. Funahashi T, Matsuzawa Y (2007) Metabolic syndrome: clinical concept and molecular basis. Ann Med 39: 482--494.
3. Matsuzawa Y, Funahashi T, Nakamura T (2011) The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 18: 629-639.
4. Kishida K, Funahashi T, Shimomura I (2012) Clinical importance of assessment of type 2 diabetes mellitus with visceral obesity. A Japanese perspective. Curr Diabetes Rev 8: 84-91.
5. Maeda K, Okubo K, Shimomura I, Mizuno K, Matsuzawa Y, et al. (1997) Analysis of an expression profile of genes in the human adipose tissue. Gene 190: 227-235.
6. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, et al. (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221: 286-289.
7. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M (1996) Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 120: 803-812.
8. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270: 26746-26749.
9. Hu E, Liang P, Spiegelman BM (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271: 10697-10703.
10. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, et al. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83.
11. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, et al. (2003) Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289: 1799-1804.
12. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, et al. (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86: 3815-3819.
13. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, et al. (2002) Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51: 2734-2741.
14. Xu A, Chan KW, Hoo RL, Wang Y, Tan KC, et al. (2005) Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280: 18073-18080.
15. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599.
16. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, et al. (2002) Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 51: 1884-1888.
17. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, et al. (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360: 57-58.
18. Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, et al. (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361: 226-228.
19. Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, et al. (2003) Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care 26: 2015-2020.
20. Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, et al. (2004) Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 53: 2473-2478.
21. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, et al. (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23: 85-89.
22. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, et al. (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730-1737.
23. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, et al. (2004) Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43: 1318-1323.
24. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, et al. (2003) Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 16: 72-75.
25. Kondo H, Shimomura I, Matsukawa Y, Kumada M, Takahashi M, et al. (2002) Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 51: 2325-2328.
26. Ohashi K, Ouchi N, Kihara S, Funahashi T, Nakamura T, et al. (2004) Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol 43: 1195-1200.
27. Kissebah AH, Sonnenberg GE, Myklebust J, Goldstein M, Broman K, et al. (2000) Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA 97: 14478-14483.
28. Vionnet N, Hani EH, Dupont S, Gallina S, Francke S, et al. (2000) Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 67: 1470-1480.
29. Mori Y, Otabe S, Dina C, Yasuda K, Populaire C, et al. (2002) Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and 11p. Diabetes 51: 1247-1255.
30. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, et al. (2005) Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112: 1756-1762.
31. Tamura T, Furukawa Y, Taniguchi R, Sato Y, Ono K, et al. (2007) Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J 71: 623-630.
32. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi SP, et al. (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13: 134--141.
33. Iwashima Y, Horio T, Kumada M, Suzuki Y, Kihara S, et al. (2006) Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol 98: 1603-1608.
34. Stenvinkel P, Marchlewska A, Pecoits-Filho R, Heimbürger O, Zhang Z, et al. (2004) Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 65: 274-281.
35. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, et al. (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50: 2094-2099.
36. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, et al. (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52: 1655-1663.
37. Hiuge-Shimizu A, Maeda N, Hirata A, Nakatsuji H, Nakamura K, et al. (2011) Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone. Arterioscler Thromb Vasc Biol 31: 792-799.
38. Hiuge A, Tenenbaum A, Maeda N, Benderly M, Kumada M, et al. (2007) Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 27: 635-641.
39. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, et al. (2009) Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 53: 2070-2077.
40. Nakatsuji H, Maeda N, Hibuse T, Hiuge A, Hirata A, et al. (2010) Reciprocal regulation of natriuretic peptide receptors by insulin in adipose cells. Biochem Biophys Res Commun 392: 100-105.
41. Lo J, Bernstein LE, Canavan B, Torriani M, Jackson MB, et al. (2007) Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am J Physiol Endocrinol Metab 293: E102-E109.
42. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, et al. (2006) Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 70: 1717-1724.
43. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, et al. (2003) Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42: 76-81.
44. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, et al. (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114: 1752-1761.
45. Funder JW (2005) Mineralocorticoid receptors: distribution and activation. Heart Fail Rev 10: 15-22.
46. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, et al. (2001) A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166-2170.
47. Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, et al. (2009) Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 84: 164-172.
48. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, et al. (2008) Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 117: 2253-2261.
49. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, et al. (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8: 731-737.
50. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, et al. (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277: 25863-25866.
51. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, et al. (2002) Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277: 37487-37491.
52. Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, et al. (2004) Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109: 2046-2049.
53. Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, et al. (2007) Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 117: 375-386.
54. Ohashi K, Parker JL, Ouchi N, Higuchi A, Vita JA, et al. (2010) Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 285: 6153-6160.
55. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, et al. (2003) Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125: 1796-1807.
56. Fujita K, Maeda N, Sonoda M, Ohashi K, Hibuse T, et al. (2008) Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPARalpha. Arterioscler Thromb Vasc Biol 28: 863-870.
57. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, et al. (2004) Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10: 1384-1389.
58. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, et al. (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX--2-dependent mechanisms. Nat Med 11: 1096-1103.
59. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, et al. (2003) Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9: 5699-5704.
60. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, et al. (2004) Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89: 1102-1107.
61. Hebbard LW, Garlatti M, Young LJ, Cardiff RD, Oshima RG, et al. (2008) T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res 68: 1407-1416.
62. Kamada Y, Matsumoto H, Tamura S, Fukushima J, Kiso S, et al. (2007) Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 47: 556-564.
63. Fujisawa T, Endo H, Tomimoto A, Sugiyama M, Takahashi H, et al. (2008) Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut 57: 1531-1538.
64. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762-769.
65. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, et al. (2004) T-cadherin is a receptor for hexameric and highmolecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 101: 10308-10313.
66. Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, et al. (2007) Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 117: 375-386.
67. Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz Lozano P, et al. (2010) T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 120: 4342-4352.
68. Shepherd PR, Kahn BB (1999) Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N Engl J Med 341: 248-257.
69. Stremmel W, Strohmeyer G, Borchard F, Kochwa S, Berk PD (1985) Isolation and partial characterization of a fatty acid binding protein in rat liver plasma membranes. Proc Natl Acad Sci USA 82: 4-8.
70. Ibrahimi A, Sfeir Z, Magharaie H, Amri EZ, Grimaldi P, et al. (1996) Expression of the CD36 homolog (FAT) in fibroblast cells: effects on fatty acid transport. Proc Natl Acad Sci USA 93: 2646-2651.
71. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N (1998) Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem 273: 16710-16714.
72. Schaffer JE, Lodish HF (1994) Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell 79: 427-436.
73. Londos C, Brasaemle DL, Schultz CJ, Adler-Wailes DC, Levin DM, et al. (1999) On the control of lipolysis in adipocytes. Ann NY Acad Sci 892: 155-168.
74. Kuriyama H, Kawamoto S, Ishida N, Ohno I, Mita S, et al. (1997) Molecular cloning and expression of a novel human aquaporin from adipose tissue with glycerol permeability. Biochem Biophys Res Commun 241: 53-58.
75. Ishibashi K, Kuwahara M, Gu Y, Kageyama Y, Tohsaka A, et al. (1997) Cloning and functional expression of a new water channel abundantly expressed in the testis permeable to water, glycerol, and urea. J Biol Chem 272: 20782-20786.
76. Kishida K, Kuriyama H, Funahashi T, Shimomura I, Kihara S, et al. (2000) Aquaporin adipose, a puta tive glycerol channel in adipocytes. J Biol Chem 275: 20896-20902.
77. Kishida K, Shimomura I, Nishizawa H, Maeda N, Kuriyama H, et al. (2001) Enhancement of the aquaporin adipose gene expression by a peroxisome proliferator-activated receptor gamma. J Biol Chem 276: 48572-48579.
78. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, et al. (2002) A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 8: 1122-1128.
79. Kishida K, Shimomura I, Kondo H, Kuriyama H, Makino Y, et al. (2001) Genomic structure and insulinmediated repression of the aquaporin adipose (AQPap), adipose-specific glycerol channel. J Biol Chem 276: 36251-36260.
80. Kondo H, Shimomura I, Kishida K, Kuriyama H, Makino Y, et al. (2002) Human aquaporin adipose (AQPap) gene. Genomic structure, promoter analysis and functional mutation. Eur J Biochem 269: 1814-1826.
81. Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, et al. (1995) Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci USA 92: 1013-1017.
82. Kuriyama H, Shimomura I, Kishida K, Kondo H, Furuyama N, et al. (2002) Coordinated regulation of fatspecific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9. Diabetes 51: 2915-2921.
83. Rodríguez A, Catalán V, Gómez Ambrosi J, García Navarro S, Rotellar F, et al. (2011) Insulin- and leptinmediated control of aquaglyceroporins in human adipocytes and hepatocytes is mediated via the PI3K/Akt/ mTOR signaling cascade. J Clin Endocrinol Metab 96: E586- E597.
84. Maeda N, Funahashi T, Hibuse T, Nagasawa A, Kishida K, et al. (2004) Adaptation to fasting by glycerol transport through aquaporin 7 in adipose tissue. Proc Natl Acad Sci USA 101: 17801-17806.
85. Hibuse T, Maeda N, Funahashi T, Yamamoto K, Nagasawa A, et al. (2005) Aquaporin 7 deficiency is associated with development of obesity through activation of adipose glycerol kinase. Proc Natl Acad Sci USA 102: 10993-10998.
86. Hara-Chikuma M, Sohara E, Rai T, Ikawa M, Okabe M, et al. (2005) Progressive adipocyte hypertrophy in aquaporin-7-deficient mice: adipocyte glycerol permeability as a novel regulator of fat accumulation. J Biol Chem 280: 15493-15496.
87. Yeh JI, Charrier V, Paulo J, Hou L, Darbon E, et al. (2004) Structures of enterococcal glycerol kinase in the absence and presence of glycerol: correlation of conformation to substrate binding and a mechanism of activation by phosphorylation. Biochemistry 43: 362-373.
88. Hibuse T, Maeda N, Nagasawa A, Funahashi T (2006) Aquaporins and glycerol metabolism. Biochim Biophys Acta 1758: 1004-1011.
89. Butler TL, Au CG, Yang B, Egan JR, Tan YM, et al. (2006) Cardiac aquaporin expression in humans, rats, and mice. Am J Physiol Heart Circ Physiol 291: H705-H713.
90. Egan JR, Butler TL, Au CG, Tan YM, North KN, et al. (2006) Myocardial water handling and the role of aquaporins. Biochim Biophys Acta 1758: 1043-1052.
91. Huss JM, Kelly DP (2005) Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 115: 547-555.
92. Abozguia K, Clarke K, Lee L, Frenneaux M (2006) Modification of myocardial substrate use as a therapy for heart failure. Nat Clin Pract Cardiovasc Med 3: 490-498.
93. Neubauer S (2007) The failing heart--an engine out of fuel. N Engl J Med 356: 1140-1151.
94. Huss JM, Kelly DP (2004) Nuclear receptor signaling and cardiac energetics. Circ Res 95: 568-578.
95. Gladka M, El Azzouzi H, De Windt LJ, da Costa Martins PA (2009) Aquaporin 7: the glycerol aquaeductus in the heart. Cardiovasc Res 83: 3-4.
96. Hibuse T, Maeda N, Nakatsuji H, Tochino Y, Fujita K, et al. (2009) The heart requires glycerol as an energy substrate through aquaporin 7, a glycerol facilitator. Cardiovasc Res 83: 34-41.